Literature DB >> 3552679

Towards improved control of atrial fibrillation.

K S Channer, M Papouchado, M A James, D W Pitcher, J R Rees.   

Abstract

Patients with atrial fibrillation frequently show a wide variation in heart rate with digoxin therapy. We have compared the effect on heart rate variability, of doubling the digoxin dosage or adding verapamil 120 mg daily in a randomized cross-over study in 14 patients. Twenty-four hour ambulatory electrocardiographic recordings, six minute walking tests and palpitation and breathlessness scores were obtained on each regime. All patients exhibited a diurnal pattern in heart rate variability. Both treatments significantly lowered heart rate but high dose digoxin lowered minimum heart rate significantly more than digoxin and verapamil, causing more night time bradycardia. Overall, digoxin with verapamil produced significantly less heart rate variability than digoxin alone. Day time but not night time pauses were prolonged by digoxin and verapamil but were prolonged more by high dose digoxin. Five (36%) patients had serum digoxin levels in the toxic range when taking high dose digoxin. Palpitations were significantly reduced by both treatments but most improvement occurred with digoxin and verapamil. No significant effect was found on six minute walking distances or breathlessness scores. In conclusion, the addition of verapamil to digoxin was superior to increasing the dose of digoxin alone, producing significantly better control of heart rate variability with less night time bradycardia.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3552679     DOI: 10.1093/oxfordjournals.eurheartj.a062241

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  9 in total

1.  Rate control in permanent atrial fibrillation.

Authors:  Theodora Nikolaidou; Kevin S Channer
Journal:  BMJ       Date:  2007-11-24

Review 2.  Current management of symptomatic atrial fibrillation.

Authors:  K S Channer
Journal:  Drugs       Date:  2001       Impact factor: 9.546

3.  The drug treatment of atrial fibrillation.

Authors:  K S Channer
Journal:  Br J Clin Pharmacol       Date:  1991-09       Impact factor: 4.335

4.  What is meant by a "controlled" ventricular rate in atrial fibrillation?

Authors:  J M Rawles
Journal:  Br Heart J       Date:  1990-03

Review 5.  Rate control in atrial fibrillation: choice of treatment and assessment of efficacy.

Authors:  Giuseppe Boriani; Mauro Biffi; Igor Diemberger; Cristian Martignani; Angelo Branzi
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 6.  Calcium channel antagonists. Part III: Use and comparative efficacy in hypertension and supraventricular arrhythmias. Minor indications.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1988-03       Impact factor: 3.727

7.  Placebo controlled trial of xamoterol versus digoxin in chronic atrial fibrillation.

Authors:  E L Ang; W L Chan; J G Cleland; D Moore; S J Krikler; N D Alexander; C M Oakley
Journal:  Br Heart J       Date:  1990-10

8.  Beta-adrenoceptor blockers in atrial fibrillation: the importance of partial agonist activity.

Authors:  K S Channer; M A James; T MacConnell; J R Rees
Journal:  Br J Clin Pharmacol       Date:  1994-01       Impact factor: 4.335

Review 9.  Digoxin for atrial fibrillation and atrial flutter: A systematic review with meta-analysis and trial sequential analysis of randomised clinical trials.

Authors:  Naqash J Sethi; Emil E Nielsen; Sanam Safi; Joshua Feinberg; Christian Gluud; Janus C Jakobsen
Journal:  PLoS One       Date:  2018-03-08       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.